Trisalus Life Sciences Inc (TLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 69 | 51 | 201 | 278 | 643 |
| TOTAL | $266 | $347 | $526 | $702 | $1,167 |
| Non-Current Assets | |||||
| Investments And Advances | 250,288 | 250,054 | 250,007 | 250,059 | 250,041 |
| TOTAL | $250,288 | $250,054 | $250,007 | $250,059 | $250,041 |
| Total Assets | $250,555 | $250,400 | $250,533 | $250,762 | $251,208 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 0 | 0 | 1,058 | 0 | 0 |
| Accrued Expenses | 765 | 1,272 | N/A | 697 | 354 |
| TOTAL | $1,737 | $2,081 | $1,602 | $697 | $354 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 251,610 | 253,449 | 256,899 | 260,928 | 237,104 |
| TOTAL | $260,360 | $262,199 | $265,649 | $269,678 | $245,854 |
| Total Liabilities | $262,097 | $264,281 | $267,250 | $270,375 | $246,208 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 31,250 | 31,250 | 31,250 | 31,250 | 31,250 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -11,543 | -13,881 | -16,718 | -19,613 | -705 |
| TOTAL | $-11,542 | $-13,880 | $-16,717 | $-19,613 | $5,000 |
| Total Liabilities And Equity | $250,555 | $250,400 | $250,533 | $250,762 | $251,208 |